Thrombotic Microangiopathy in Patients Treated with <sup>177</sup> Lu-PSMA Combination Therapies
Lu-PSMA-associated TMA is a rare but a potentially severe complication of treatment. The contribution of initial versus cumulative renal absorbed dose remains unclear, and early dosimetry may help identify at-risk patients.
Authors
- Joanna C. Chan
- Nadia Hitchen (ORCID: https://orcid.org/0000-0001-9327-4171)
- M. Carroll
- Irene Ruderman (ORCID: https://orcid.org/0000-0001-6580-1464)
- Michael S. Hofman (ORCID: https://orcid.org/0000-0001-8622-159X)
- Mark K. Tiong (ORCID: https://orcid.org/0000-0001-9348-4638)
- Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
- Jo Hudson
- Pratheepan Puvanakumar
- James P. Buteau
- Price Jackson
- Lewis Au
- Shahneen Sandhu
- Sevastjian Kranz
- Louise K. Kostos
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-04-22
- DOI
- https://doi.org/10.2967/jnumed.126.272085
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00